نتایج جستجو برای: hormone refractory prostate cancer

تعداد نتایج: 1104273  

Journal: :international journal of hematology-oncology and stem cell research 0
mozaffar aznab imam reza hospital and taleghani hospital, kermanshah university of medical sciences, kermanshah, iran bahram samadzadeh imam reza hospital, kermanshah university of medical sciences, kermanshah, iran assad moradi imam reza hospital, kermanshah university of medical sciences, kermanshah, iran abdol rosol bardideh imam reza hospital, kermanshah university of medical sciences, kermanshah, iran jamal hoseini clinical research developemental center, kermanshah university of medical sciences, kermanshah, iran kazhal kaviani moghadam statistic department, private statistic institute, kermanshah, iran

introduction: prostate cancer is one of the most common cancers among males and the second factor resulting to death due to cancer among them.(1) the median age of its diagnosis is 65 years. the initial treatment includes androgen ablation or orchiectomy.(2, 3) in case of patient’s hormone refractory, chemotherapy would be substituted. the objective of this study is the consideration of intermi...

Journal: :middle east journal of cancer 0
mina tajvidi department of radiation oncology, school of medicine, isfahan university of medical sciences, isfahan, iran mahnaz roayaei department of radiation oncology, school of medicine, isfahan university of medical sciences, isfahan, iran simin hematti department of radiation oncology, school of medicine, isfahan university of medical sciences, isfahan, iran hadi faezi department of radiation oncology, school of medicine, isfahan university of medical sciences, isfahan, iran

background: metastatic prostate cancer is one of the most important cancers among men worldwide. androgen ablation therapy can be used in treatment of these patients; however, most will progress to metastatic hormone-refractory prostate cancer. in this regard, docetaxel has been approved to treat metastatic hormone-refractory prostate cancer in the united states. in this study, we aimed to inve...

2012
Masayoshi Zaitsu Mariko Yamanoi Koji Mikami Yuta Takeshima Naohiko Okamoto Sadao Imao Akiko Tonooka Takumi Takeuchi

Background. Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist, but finally castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to "the castration level" by LHRH agonists but may not get low enough against castration-refractory prostate cancer. Methods. As case series, twelve patients suffering from hormone-re...

Journal: :middle east journal of cancer 0
amal halim department of clinical oncology and nuclear medicine, faculty of medicine, mansoura university, mansoura, egypt

background : this study retrospectively evaluated the prognostic factors and treatment outcome of patients with hormone-refractory prostate cancer who received chemotherapy. methods :we reviewed records of hormone-refractory prostate cancer patients who received chemotherapy between december 2004 and may 2011 at the clinical oncology and nuclear medicine department, mansoura university and the ...

Journal: :Molecular cancer therapeutics 2008
Yuexing Zhang Douglas Linn Zhenqiu Liu Jonathan Melamed Fabio Tavora Charles Y Young Angelika M Burger Anne W Hamburger

Aberrant activation of the androgen receptor (AR) by the ErbB2/ErbB3 heterodimer contributes to the development of hormone resistance in prostate cancer. EBP1, an ErbB3-binding protein, acts as an AR corepressor. As EBP1 is decreased in preclinical models of hormone-refractory prostate cancer, we studied the expression of EBP1 in human prostate cancer. We found that the expression of the EBP1 g...

Journal: :Journal of the National Cancer Institute 1999
L Bubendorf M Kolmer J Kononen P Koivisto S Mousses Y Chen E Mahlamäki P Schraml H Moch N Willi A G Elkahloun T G Pretlow T C Gasser M J Mihatsch G Sauter O P Kallioniemi

BACKGROUND The molecular mechanisms underlying the progression of prostate cancer during hormonal therapy have remained poorly understood. In this study, we developed a new strategy for the identification of differentially expressed genes in hormone-refractory human prostate cancer by use of a combination of complementary DNA (cDNA) and tissue microarray technologies. METHODS Differences in g...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Zhennan Gu Mark A Rubin Yu Yang Samuel E Deprimo Hongjuan Zhao Steven Horvath James D Brooks Massimo Loda Robert E Reiter

The diagnosis and management of prostate cancer is hampered by the absence of markers capable of identifying patients with metastatic disease. In order to identify potential new markers for prostate cancer, we compared gene expression signatures of matched androgen-dependent and hormone refractory prostate cancer xenografts. One candidate gene overexpressed in a hormone refractory xenograft was...

Journal: :Nutrition and cancer 2009
Jamal Mahajna Nesly Dotan Ben-Zion Zaidman Roumyana D Petrova Solomon P Wasser

Prostate cancer (PCa) is the most common male malignancy in many Western countries. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops to hormone-refractory tumors due to the accumulation of mutations in the androgen receptor and/or the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of prostate canc...

Journal: :Asian journal of andrology 2009
Kaori Yamamoto-Ishikawa Hiroyoshi Suzuki Masahiko Nezu Naoto Kamiya Takashi Imamoto Akira Komiya Kazuyuki Sogawa Takeshi Tomonaga Fumio Nomura Tomohiko Ichikawa

Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients' s...

2014
Oliver Richmond Maryam Ghotbaddini Cidney Allen Alice Walker Shokouh Zahir Joann B. Powell

BACKGROUND Distant prostate cancers are commonly hormone refractory and exhibit increased growth no longer inhibited by androgen deprivation therapy. Understanding all molecular mechanisms contributing to uncontrolled growth is important to obtain effective treatment strategies for hormone refractory prostate cancers (HRPC). The aryl hydrocarbon receptor (AhR) affects a number of biological pro...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید